Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Status:
Completed
Trial end date:
2015-04-09
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating
patients with newly diagnosed acute myeloid leukemia who have received chemotherapy.